Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

Back at the be­gin­ning of 2018, Clay Sie­gall snagged a can­cer drug called tu­ca­tinib with a $614 mil­lion cash deal to buy Cas­ca­di­an. It paid off to­day with a sol­id set of mid-stage da­ta for HER2 pos­i­tive breast can­cer that will in turn serve as the piv­otal win Sie­gall needs to seek an ac­cel­er­at­ed ap­proval in the push for a new triplet ther­a­py.

And if all the cards keep falling in its fa­vor, they’ll move from 1 drug on the mar­ket to 3 in 2020, which is shap­ing up as a land­mark year as Seat­tle Ge­net­ics pre­pares for its 23rd an­niver­sary on Ju­ly 15.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER